Showing 3151-3160 of 5646 results for "".
- First-Of-Its-Kind Visual Prosthesis Brain Implant Developed in Chicago Moves to Clinical Trialhttps://modernod.com/news/first-of-its-kind-visual-prosthesis-brain-implant-developed-in-chicago-moves-to-clinical-trial/2479367/The Intracortical Visual Prosthesis (ICVP) is an implant that connects directly to the brain’s visual cortex, bypassing the retina and optic nerves. The National Institutes of Health has awarded Illinois Tech researchers $2.5 million for the first year of a 3-year project that includes implanting
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical
- Sight Sciences Pitches $150M IPO for Its Glaucoma, Dry Eye Deviceshttps://modernod.com/news/sight-sciences-pitches-150m-ipo-for-its-glaucoma-dry-eye-devices/2479355/Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO, according to a Fierce Biotech report. By going public, the Menlo Par
- Ocugen Climbs on Phase 3 COVID Vaccine Data, Hitting Back at Delta Varianthttps://modernod.com/news/ocugen-climbs-on-phase-3-covid-vaccine-data-hitting-back-at-delta-variant/2479348/After seeing its stock fall consistently over the past few months, Ocugen and partner Bharat Biotech have posted some encouraging data from their pandemic vaccine Covaxin, according to a FierceBiotech report. The latest look from its lat
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels
- Prevent Blindness Declares July as Dry Eye Awareness Monthhttps://modernod.com/news/prevent-blindness-declares-july-as-dry-eye-awareness-month/2479328/Nearly 16 million Americans have dry eye, according to the
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Two Shots of Pfizer, AstraZeneca COVID-19 Vaccines Effective Against Delta Variant: Studyhttps://modernod.com/news/two-shots-of-pfizer-astrazeneca-covid-19-vaccines-effective-against-delta-variant-study/2479295/A real world study conducted by Public Health England shows tha
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive